News & Views
Agreement takes Gene Editing to Japanese Pharma
Feb 25 2020 Read 326 Times
A licensing agreement between Daiichi Sankyo and ERS Genomics provides the Japanese pharmaceutical company with access to foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, for use in its internal research and development to address areas of unmet medical need.
Eric Rhodes, CEO of ERS Genomics, said: “Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations.”
The Dublin-based company holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - The Movement Towards More Comprehensive Testing of Mycotoxins in Cannabis - Addressing proper HACCP implementation - Micropatterning: The art of micro-controlling...
View all digital editions
Jan 20 2021 Tokyo, Japan & online
Jan 23 2021 Digital Event
Jan 26 2021 Virtual event
Feb 23 2021 Cologne, Germany
Feb 28 2021 Virtual event